Organon Acquires Alydia Health

Laborie Acquires the JADA® System from Organon

January 28, 2026

Medical Devices

Laborie Medical Technologies has completed the acquisition of the JADA® System and the team behind it from Organon in a transaction announced in late January 2026. The deal — part of Organon’s divestiture program (previously disclosed as up to $465 million) — brings more than 90 employees and an FDA-cleared device for rapid control of postpartum hemorrhage into Laborie’s obstetrics portfolio to expand the company’s maternal health capabilities.

Hologic Acquires Gynesonics

January 6, 2025

Medical Devices

Hologic has completed the acquisition of Gynesonics for approximately $350 million. The purchase adds the Sonata System — a minimally invasive intrauterine ultrasound-guided radiofrequency ablation platform for treating uterine fibroids — to Hologic's portfolio, expanding its capabilities in women's health surgical solutions.

Danaher Acquires Aldevron for $9.6 Billion

June 17, 2021

Biotechnology

Danaher Corporation entered into a definitive agreement to acquire Aldevron from EQT Private Equity for an enterprise value of approximately USD 9.6 billion. Aldevron, headquartered in Fargo, North Dakota with ~600 employees and additional operations in Madison, Wisconsin, will operate as a standalone company within Danaher's Life Sciences segment to expand Danaher's capabilities in genomic medicine and biologics manufacturing.

Organon Acquires Forendo Pharma

December 13, 2021

Biotechnology

Organon completed the acquisition of Forendo Pharma, a Turku-based clinical-stage biopharmaceutical company focused on women's health, including a Phase 2 candidate FOR-6219 for endometriosis and a preclinical program for PCOS. Consideration includes $75 million upfront, assumption of ~$9 million debt, up to $270 million in development/regulatory milestones and up to $600 million in commercial milestones (total potential consideration up to $954 million).

AbbVie Acquires Aliada Therapeutics for $1.4 Billion

December 11, 2024

Biotechnology

AbbVie has completed the $1.4 billion acquisition of Aliada Therapeutics, a RA Capital- and JJDC-backed biotech developing ALIA-1758, an anti‑pyroglutamate amyloid beta antibody that uses a blood‑brain‑barrier crossing technology for Alzheimer's disease. The deal brings Aliada's CNS drug‑delivery platform and lead Phase 1 asset into AbbVie's neuroscience pipeline and represents an exit for RA Capital's Raven incubator and other early investors.

W2O Acquires Elysia Group

September 24, 2020

Healthcare Services

W2O has acquired Elysia Group, a health economics and outcomes research (HEOR) consultancy that operates in the United States and Asia Pacific. The founders of Elysia joined W2O to lead its Health Economics and Real-World Evidence practice and the capability will integrate with W2O's recently acquired Discern Health to expand market access and evidence-generation services.